Become a member
Submit your news
news by category
-
Academia
Activism
Business Ethics
Clean Technology
Community Development
Corporate Governance
Corporate Social Responsibility
Diversity & Human Resource
Environment
Events
Fair Trade & Supply Chain
Finance
Green Building
Green Jobs & Career News
Green Products & Services
Health & Wellness
Human Rights
Other
Philanthropy & Corporate Contributions
Ratings & Awards
Renewable & Alternative Energy
Research, Reports & Publications
Socially Responsible Investing
Sustainability
Volunteerism
Workplace Issues
More Information
- Distribution
- About us
- Services
- Archive
- Contact
- Categories
- Subscribe
-
Subscribe to alerts
Subscribe to rss
Street Smart Sustainability
Must Read the new book Street Smart Sustainability by co-authors Joe Sibilia and David Mager.
CSR Press Release
Print
Alerts
Send to FriendOCEG Launches Pharmaceutical Sales and Marketing Supplement for Public Industry Comment
Submitted by: OCEG - Open Compliance & Ethics Group
Categories: Business Ethics, Corporate Governance
Posted: Feb 14, 2008 – 09:41 AM EST
PHOENIX, AZ. February 14, 2008 – The Open Compliance and Ethics Group (OCEG) today launched the public exposure draft of the Pharmaceutical Sales and Marketing Supplement, an interactive database designed to assist the pharmaceutical industry in understanding legal and regulatory requirements, as well as core business practices, of the Pharmaceutical Sales and Marketing Compliance Program. OCEG will accept public comments on the Supplement through March 31, 2008 at http://www.oceg.org/View/PharmaSM.
"Understanding and implementing the requirements for a company's compliance program can be a daunting task for any executive," says OCEG CEO Scott Mitchell. "The Pharmaceutical Sales and Marketing Supplement public exposure draft gives executives an opportunity to provide commentary on guidelines that are intended to be the gold standard for compliance issues in the pharmaceutical industry. The public exposure and commentary period serves as an opportunity for those most impacted to express their views on the issues around practical business implementation of these guidelines."
Best practices addressed in the Supplement include:
OCEG worked with Ernst & Young LLP and the law firm of Hogan & Hartson LLP in writing the Supplement. Members of both firms donated their time to develop the content. They were supported by an Advisory Board of experts who offered comments in the initial scoping of the Supplement structure and reviewed drafts of the guidance.
"This resource will help companies navigate the global compliance waters," says Ted Acosta, Health Sciences Leader in Ernst & Young's, Fraud Investigations & Dispute Services.. "On one hand, users will learn the codes and regulations and the consequences of non-compliance. Yet on the other, it will offer practices and tools from companies with tried and true compliance programs."
"The Supplement is about going beyond the basics of compliance," says Hogan & Hartson Partner Helen Trilling. "Our goal in working with OCEG was to provide in-depth guidance – that surpasses the resources available to date – to assist companies in developing compliance policies geared to meeting applicable legal requirements, government guidance, and industry standards."
"Whether a start-up pharma or biotech company is investigating how to build a compliance infrastructure or a big pharma company is assessing the effectiveness of its compliance program, this will be a global online resource with insights into which programs are practiced around the world," says Dave DeMarco, Ernst & Young Pharmaceutical OCEG Domain Leader. "We anticipate the standards and insights provided will spawn a healthy dialogue between the audit and compliance organizations." The OCEG Pharmaceutical Sales and Marketing Supplement is available to review at http://www.oceg.org/landing/ExposureDrafts.aspx#
BACKGROUND
OCEG is the only nonprofit organization that provides
For more information, please contact: